A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis

Brad Hall, Sawsan Alyafei, Sathishkumar Ramaswamy, Shruti Sinha, Maha El Naofal, Fatma Rabea, Bryan J. Killinger, Gary J. Latham, Ahmad Abou Tayoun
doi: https://doi.org/10.1101/2024.02.22.24303180

Article Information

doi 
https://doi.org/10.1101/2024.02.22.24303180
History 
  • February 23, 2024.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.

Author Information

  1. Brad Hall1,*,
  2. Sawsan Alyafei2,*,
  3. Sathishkumar Ramaswamy2,
  4. Shruti Sinha2,
  5. Maha El Naofal2,
  6. Fatma Rabea2,3,
  7. Bryan J. Killinger1,
  8. Gary J. Latham1 and
  9. Ahmad Abou Tayoun2,4,#
  1. 1Asuragen, A Bio-Techne Brand, Texas, USA
  2. 2Genomics Center of Excellence, Al Jalila Children’s Specialty Hospital, Dubai Health, Dubai, UAE
  3. 3Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai, UAE
  4. 4Center for Genomic Discovery, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai Health, Dubai, UAE
  1. ↵#Corresponding Author
    : Ahmad Abou Tayoun; Ahmad.Tayoun{at}dubaihealth.ae

  1. ↵* Equally contributed to this work

Back to top
Posted February 23, 2024.
Download PDF

Supplementary Material

Data/Code
Email
A dual-mode targeted Nanopore sequencing assay for comprehensive SMN1 and SMN2 variant analysis
Brad Hall, Sawsan Alyafei, Sathishkumar Ramaswamy, Shruti Sinha, Maha El Naofal, Fatma Rabea, Bryan J. Killinger, Gary J. Latham, Ahmad Abou Tayoun
medRxiv 2024.02.22.24303180; doi: https://doi.org/10.1101/2024.02.22.24303180
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area